- Home
- TDTH vs BOLT Comparison
TDTH vs BOLT Comparison
Compare TDTH & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDTH
- BOLT
- Stock Information
- Founded
- TDTH 2014
- BOLT 2015
- Country
- TDTH Singapore
- BOLT United States
- Employees
- TDTH 23
- BOLT N/A
- Industry
- TDTH
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- TDTH
- BOLT Health Care
- Exchange
- TDTH NYSE
- BOLT Nasdaq
- Market Cap
- TDTH 20.0M
- BOLT 16.8M
- IPO Year
- TDTH 2024
- BOLT 2021
- Fundamental
- Price
- TDTH $0.46
- BOLT $5.96
- Analyst Decision
- TDTH
- BOLT Buy
- Analyst Count
- TDTH 0
- BOLT 3
- Target Price
- TDTH N/A
- BOLT $50.00
- AVG Volume (30 Days)
- TDTH 10.0M
- BOLT 18.0K
- Earning Date
- TDTH 07-22-2025
- BOLT 08-12-2025
- Dividend Yield
- TDTH N/A
- BOLT N/A
- EPS Growth
- TDTH N/A
- BOLT N/A
- EPS
- TDTH N/A
- BOLT N/A
- Revenue
- TDTH $465,435.00
- BOLT $3,638,000.00
- Revenue This Year
- TDTH N/A
- BOLT N/A
- Revenue Next Year
- TDTH N/A
- BOLT $24.14
- P/E Ratio
- TDTH N/A
- BOLT N/A
- Revenue Growth
- TDTH N/A
- BOLT N/A
- 52 Week Low
- TDTH $0.17
- BOLT $5.20
- 52 Week High
- TDTH $4.74
- BOLT $15.60
- Technical
- Relative Strength Index (RSI)
- TDTH N/A
- BOLT 47.50
- Support Level
- TDTH N/A
- BOLT $5.68
- Resistance Level
- TDTH N/A
- BOLT $6.40
- Average True Range (ATR)
- TDTH 0.00
- BOLT 0.31
- MACD
- TDTH 0.00
- BOLT 0.07
- Stochastic Oscillator
- TDTH 0.00
- BOLT 50.00
About TDTH TRIDENT DIGITAL TECH HOLDINGS LTD SPON ADS EACH REP 8 ORD CL B
Trident Digital Tech Holdings Ltd is principally engaged in the provision of business consulting service and IT customization solutions in the Republic of Singapore. Its revenue is derived from business consulting service, IT customization and selling event tickets.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.